Compare Eli Lilly And Co (LLY) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Nuscale Power Corporation — how do they compare? Eli Lilly And Co trades at $1,221.01 (market cap $1.08T), while Nuscale Power Corporation trades at $9.61 (market cap $4.06B). The key difference: Eli Lilly And Co is far larger — about 266× Nuscale Power Corporation's market cap, and Eli Lilly And Co pays a 0.57% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals.
| LLY | SMR | |
|---|---|---|
Market Cap | $1.08T | $4.06B |
Sector | Health | Utilities |
52-Week High | $1.24K | $53.43 |
52-Week Low | $639.43 | $7.59 |
Enterprise Value | $1.13T | $2.99B |
Dividend Yield | 0.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
NuScale Power (SMR) trades at $9.58, up 4.36% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $355.79 million on $31.48 million revenue in 2025, with a negative net margin of -3,888.7%. Recent news highlights regulatory progress for its small modular reactors and potential from AI data center power demand, though revenue plunged 98.8% year-over-year in Q2 2026.
Outlook hinges on commercial deployment success, with a consensus price target of $10.50 offering 9.6% upside. High execution risk and cash burn are key concerns, but analyst sentiment is 50% buy-rated. Investors face volatility from project timelines versus speculative growth potential in nuclear energy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
